loading
Madrigal Pharmaceuticals Inc stock is traded at $298.40, with a volume of 300.05K. It is down -0.26% in the last 24 hours and up +7.48% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$299.17
Open:
$298.92
24h Volume:
300.05K
Relative Volume:
0.89
Market Cap:
$6.63B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-11.88
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-10.69%
1M Performance:
+7.48%
6M Performance:
-9.06%
1Y Performance:
+5.27%
1-Day Range:
Value
$296.17
$301.82
1-Week Range:
Value
$296.17
$337.40
52-Week Range:
Value
$200.63
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
Name
Madrigal Pharmaceuticals Inc
Name
Phone
404-380-9263
Name
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
Employee
528
Name
Twitter
@MadrigalPharma
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MDGL's Discussions on Twitter

Compare MDGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
298.40 6.64B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Upgrade B. Riley Securities Neutral → Buy
Feb-27-25 Reiterated H.C. Wainwright Buy
Jun-28-24 Initiated Cantor Fitzgerald Neutral
Jun-11-24 Initiated Wolfe Research Outperform
Apr-22-24 Initiated BofA Securities Underperform
Mar-15-24 Upgrade B. Riley Securities Sell → Neutral
Mar-06-24 Initiated Citigroup Buy
Feb-26-24 Downgrade B. Riley Securities Neutral → Sell
Dec-20-22 Reiterated Oppenheimer Outperform
Dec-19-22 Reiterated H.C. Wainwright Buy
Dec-19-22 Reiterated Piper Sandler Overweight
Dec-19-22 Upgrade Raymond James Underperform → Mkt Perform
Jul-08-22 Downgrade B. Riley Securities Buy → Neutral
Oct-07-21 Initiated Jefferies Buy
Aug-06-21 Upgrade BMO Capital Markets Market Perform → Outperform
May-20-21 Resumed Goldman Buy
Nov-24-20 Resumed Evercore ISI Outperform
Nov-06-20 Reiterated H.C. Wainwright Buy
Jul-31-20 Initiated Piper Sandler Overweight
Jun-05-20 Initiated BMO Capital Markets Market Perform
May-05-20 Initiated Chardan Capital Markets Buy
Jan-30-20 Initiated Canaccord Genuity Buy
Jan-09-20 Upgrade UBS Neutral → Buy
Nov-07-19 Reiterated H.C. Wainwright Buy
Jun-25-19 Initiated Stifel Hold
Jun-10-19 Upgrade B. Riley FBR Neutral → Buy
Feb-28-19 Reiterated H.C. Wainwright Buy
Feb-22-19 Initiated SVB Leerink Outperform
Jan-23-19 Initiated UBS Neutral
Dec-14-18 Initiated Wolfe Research Outperform
Dec-12-18 Initiated B. Riley FBR Neutral
Nov-19-18 Downgrade Raymond James Mkt Perform → Underperform
Nov-16-18 Upgrade Evercore ISI In-line → Outperform
Sep-04-18 Initiated Citigroup Buy
Aug-06-18 Downgrade Goldman Buy → Neutral
Jun-28-18 Initiated Raymond James Mkt Perform
View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

pulisher
05:07 AM

Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockDiscover breakthrough stocks before the crowd - jammulinksnews.com

05:07 AM
pulisher
Jul 26, 2025

Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion - MSN

Jul 26, 2025
pulisher
Jul 26, 2025

Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire

Jul 25, 2025
pulisher
Jul 25, 2025

Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financia - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Madrigal Pharmaceuticals, Inc. Announces Second-Quarter 2025 Financial Results Release and Webcast Details - Quiver Quantitative

Jul 25, 2025
pulisher
Jul 25, 2025

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 24, 2025

Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Madrigal Pharmaceuticals: Strategic Financing and Growth Potential Justify Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Madrigal Pharmaceuticals Inc. stock priceHigh-velocity gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal's $500M Financing: Cementing Leadership in the High-Growth MASH Market - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500M Credit Facility - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal secures $500 million credit facility to advance MASH pipeline - Investing.com Australia

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal Pharmaceuticals Secures $500 Million Senior Secured Credit Facility to Enhance MASH Pipeline and Support Strategic Expansion - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Madrigal secures $500 million credit facility to advance MASH pipeline By Investing.com - Investing.com UK

Jul 22, 2025
pulisher
Jul 22, 2025

Citizens JMP reiterates Madrigal stock rating on strong Rezdiffra uptake By Investing.com - Investing.com Canada

Jul 22, 2025
pulisher
Jul 21, 2025

10 Most Undervalued Healthcare Stocks to Buy According to Analysts - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Madrigal gains after Rezdiffra patent win - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN

Jul 19, 2025
pulisher
Jul 17, 2025

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

Jul 17, 2025

Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Madrigal Pharmaceuticals Inc Stock (MDGL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Taub Rebecca
Director
Jul 18 '25
Sale
350.00
1,000
350,005
461,044
FRIEDMAN PAUL A
Director
Jul 18 '25
Option Exercise
9.45
1,400
13,230
188,564
FRIEDMAN PAUL A
Director
Jul 18 '25
Sale
350.03
1,400
490,044
187,164
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):